💊 #FDA Drug Approvals — September 2026
#Lirafugratinib, #Isembyld & #Zanvastro bring new approaches targeting FGFR, myostatin & RNA.

#Sevabertinib, #Camizestrant, #Imlunestrant, #Aqneursa & #Joenja expand therapeutic options across cancer, rare diseases & genetic disorders.

The #FDA has granted accelerated approval to #sevabertinib (#Hyrnuo) for adults with locally advanced/metastatic non-squamous NSCLC harboring activating HER2 (#ERBB2) tyrosine kinase domain mutations.

SOHO-01 trial: 75% objective response rate in patients who had not received prior systemic therapy